SBIR/STTR Research Award

Identification of the Antisickling Compounds in SCD

Award identifier 273fd84cc9c062107777ae16278d4b024db6adc4be85f7722ddc57bb58fa2756Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$224,731

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INVENUX, LLC
Proposal award date
2017-07-17
Contract end date
2020-01-16
UEI
TE98A4TS48J1
Solicitation number
PA16-302
Topic code
NHLBI

Research abstract

ABSTRACT Sickle cell disease SCD affects approximately people in the United States and millions worldwide Symptoms appear shortly after birth and in less developed countries the majority of children with SCD die before the age of five In the U S SCD patients suffer chronic pain and fatigue severe acute painful crises requiring hospitalization and opiates strokes and multi organ damage and have an average mortality in their s The only FDA approved drug for adults with SCD is the anticancer drug hydroxyurea New treatments are desperately needed for both children and adults with SCD SCD is a botanical drug that inhibits red blood cell sickling in vitro and in vivo The formation of sickle shaped red blood cells caused by the polymerization of deoxygenated sickle hemoglobin is the primary and causative event in the molecular pathogenesis of sickle cell disease therefore inhibition of sickling by SCD should ameliorate the signs symptoms and slow the progression of sickle cell disease In a Phase B study SCD was shown to be safe and reduced pain and fatigue the two most common symptoms of sickle cell disease The compounds in SCD responsible for the antisickling activity are unknown as is the mechanism of antisickling Identification of the antisickling compounds would assist in clinical development and may enable the development of a more potent and effective drug for the treatment of sickle cell disease Identification of the antisickling compounds would assist in the elucidation of the mechanism by which SCD inhibits red blood cell sickling and point the way to a new target for antisickling drugs and the development of a new class of compounds to treat sickle cell disease Project Narrative About Americans have Sickle Cell Disease Those affected often have high medical costs a poor quality of life and early death Treatment options are few There is a substantial unmet medical need for new safe and effective disease modifying drugs like the one in this grant to treat this disease

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2002–2017). Reported award amounts total $2,974,411. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.